Induction of immune tolerance in kidney transplant recipients

[Alemtuzumab induction in kidney transplant recipients].

INTRODUCTION Induction therapy has been used in sensitized patients, re-transplants, and in patients who have high risk to delayed graft function (DGF) after renal transplantation. METHODS Retrospective study with aim to compare transplant endpoints between recipients of deceased donors which have received induction with alemtuzumab (n = 9) versus thymoglobulin (n = 18). Patients were matched...

Immune monitoring in kidney transplant recipients revisited.

The discovery and clinical implementation of several new immunosuppressant agents along with a variety of advances in clinical care have made a significant impact on the outcome of organ transplantation. Acute rejection rates for renal allograft recipients have fallen precipitously over the last decade, and recently reported data demonstrate prolongation of the halflives of transplanted kidneys...

Covid-19 infection in kidney transplant recipients: a case report

Immune profile of pediatric renal transplant recipients following alemtuzumab induction.

The incidence of developing circulating anti-human leukocyte antigen antibodies and the kinetics of T cell depletion and recovery among pediatric renal transplant recipients who receive alemtuzumab induction therapy are unknown. In a collaborative endeavor to minimize maintenance immunosuppression in pediatric renal transplant recipients, we enrolled 35 participants from four centers and treate...

Cataract in kidney transplant recipients.

The relationship between the administrated dose of steroid and the grade of cataract was studied in 22 kidney transplant recipients maintaining a good graft function for more than one year. Posterior subcapsular cataract was observed in 19 patients, of whom seven showed severe cataract accompanied by visual disturbance. The total dose of steroid, particularly the dose in the period from three m...